DUBLIN, Jan 17, 2017 /PRNewswire/ --
Research and Markets has announced the addition of the "Global Human Respiratory Syncytial Virus Drugs Market 2016-2020" report to their offering.
The global human respiratory syncytial virus drugs market to grow at a CAGR of 4.27% during the period 2016-2020.
Global Human Respiratory Syncytial Virus Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. To calculate the market size, the report considers the revenue generated from the sales of branded and generic drugs used to treat and prevent respiratory syncytial virus infections.
One trend in the market is emergence of new entrants likely to change market dynamics. The growing demand for novel products for the treatment of RSV has fueled the emergence of new entrants that are likely to change the market dynamics during the forecast period.
According to the report, one driver in the market is presence of large patient pool fuels market growth. RSV is the leading cause of lower respiratory tract infections in infants and young children. Each year, 4-5 million children younger than four years of age acquire an RSV infection, and more than 0.12 million are hospitalized annually in the US because of this infection. For example, approximately 25 to 40 out of 100 individuals with RSV have signs or symptoms of pneumonia or bronchiolitis. Five to 20 out of 1,000 require hospitalization.
Also, adults with compromised immune systems and of ages 65 and older are also at a higher risk of severe disease. In the US, on average, RSV leads to 57,257 hospitalizations among children of ages below 5 years; 2.1 million outpatient visits among children less than 5 years; and 0.17 million hospitalizations and 14,000 death cases among adults of ages more than 65 years. The presence of this large RSV patient pool with highly unmet medical needs with single approved therapy is expected to drive the market growth during the forecast period.
- Teva Pharmaceutical
Other Prominent Vendors:
- ADMA Biologics
- Alnylam Pharmaceuticals
- Ark Biosciences
- Aviragen Therapeutics
- Bavarian Nordic
- Boehringer Ingelheim
- Gilead Sciences
- ImmunoVaccine Technologies
- Johnson & Johnson
- Kyowa Hakko Kirin
- Mymetics Corporation
- Regeneron Pharmaceuticals
Key Topics Covered:
Part 01: Executive summary
Part 02: Scope of the report
Part 03: Market research methodology
Part 04: Introduction
Part 05: Disease overview
Part 06: Pipeline analysis
Part 07: Market landscape
Part 08: Market segmentation by category of drug
Part 09: Geographical segmentation
Part 10: Market drivers
Part 11: Impact of drivers
Part 12: Market challenges
Part 13: Impact of drivers and challenges
Part 14: Market trends
Part 15: Vendor landscape
Part 16: Key vendor analysis
Part 17: Appendix
For more information about this report visit http://www.researchandmarkets.com/research/fb6gkr/global_human
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets